Bevacizumab in brain tumors: Ready for primetime?

Future Oncology

Volumn 5, Issue 8, 2009, Pages 1183-1184

  Franceschi, Enrico ^a   Tosoni, Alicia ^a   Girardi, Fabio ^a   Brandes, Alba A ^a  

^a BELLARIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; IRINOTECAN; TEMOZOLOMIDE; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TARGETING; EDITORIAL; GLIOBLASTOMA; HUMAN; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; TUMOR VASCULARIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; HUMANS;

EID: 75649092598     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.98     Document Type: Editorial

References (11)

1. Stupp R, Mason WP, van den Bent MJ et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987-996 (2005). ■■ Milestone paper that changed the state-of-the-art treatment for glioblastoma.
2. Brandes AA, Tosoni A, Franceschi E et al.: Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed glioblastoma patients: correlation with MGMT promoter methylation status. J. Clin. Oncol. 27(8), 1275-1279 (2009).
3. Brandes AA, Tosoni A, Amista P et al.: How effective is BCNU in recurrent glioblastoma in the modern era? A Phase II trial. Neurology 63(7), 1281-1284 (2004).
4. Brandes AA, Tosoni A, Franceschi E et al.: Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a Phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother. Pharmacol. 64(4), 769-775 (2009).
5. Stark-Vance V: Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. In: World Federation of Neuro-Oncology Second Quadrennial Meeting. Edinburgh, UK, May 5-8 (2005) (Abstract 342).
6. Bokstein F, Shpigel S, Blumenthal DT: Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer 112(10), 2267-2273 (2008).
7. Cloughesy TF, Prados MD, Wen PY et al.: A Phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progressionfree survival (PFS6) in recurrent, treatmentrefractory glioblastoma (GBM). J. Clin. Oncol. (Meeting Abstracts), 26(15 Suppl.) (2008) (Abstract 2010b). ■ One of the trials evaluated by the US FDA to grant accelerated approval to bevacizumab.
8. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al.: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 25(30), 4722-4729 (2007).
9. Vredenburgh JJ, Desjardins A, Herndon JE, 2nd et al.: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer. Res. 13(4), 1253-1259 (2007).
10. Kreisl TN, Kim L, Moore K et al.: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27(5), 740-745 (2008). ■ One of the trials evaluated by the US FDA to grant accelerated approval to bevacizumab.
11. Chen W, Delaloye S, Silverman DH et al.: Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J. Clin. Oncol. 25(30), 4714-4721 (2007).